Laetitia Vanwonterghem

Laetitia Vanwonterghem

Auto-generated profile, based on publicly available information

Laetitia Vanwonterghem

Cancer Target and Experimental Therapeutics, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Grenoble Alpes University, Grenoble, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
TMThierry Michy
Thierry Michy
TMThibault Massias
Thibault Massias
CBClaire Bernard
Claire Bernard
LVLaetitia Vanwonterghem
Laetitia Vanwonterghem
MHMaxime Henry
Maxime Henry
AHAmandine HURBIN
Amandine HURBIN
Advanced ovarian cancer is the most lethal gynecological cancer, with a high rate of chemoresistance and relapse. Photodynamic therapy offers new prospects for ovarian cancer treatment, but current photosensitizers lack tumor specificity, resulting in low efficacy and significant side-effects. In the present work, the clinically approved photosensitizer verteporfin was encapsulated within nanostructured lipid carriers (NLC) for targeted photodynamic therapy of ovarian cancer. Cellular uptake and phototoxicity of free verteporfin and NLC-verteporfin were studied in vitro in human ovarian cancer cell lines cultured in 2D and 3D-spheroids, and biodistribution and photodynamic therapy were evaluated in vivo in mice. Both molecules were internalized in ovarian cancer cells and strongly inhibited tumor cells viability when exposed to laser light only. In vivo biodistribution and pharmacokinetic studies evidenced a long circulation time of NLC associated with efficient tumor uptake. Administration of 2 mg·kg−1 free verteporfin induced severe phototoxic adverse effects leading to the death of 5 out of 8 mice. In contrast, laser light exposure of tumors after intravenous administration of NLC-verteporfin (8 mg·kg−1) significantly inhibited tumor growth without visible toxicity. NLC-verteporfin thus led to efficient verteporfin vectorization to the tumor site and protection from side-effects, providing promising therapeutic prospects for photodynamic therapy of cancer.

1 April 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
VJVictor Jeannot
Victor Jeannot
CGCony Gauche
Cony Gauche
SMSilvia Mazzaferro
Silvia Mazzaferro
MCMorgane Couvet
Morgane Couvet
LVLaetitia Vanwonterghem
Laetitia Vanwonterghem
AHAmandine HURBIN
Amandine HURBIN

1 May 2016 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
VJVictor Jeannot
Victor Jeannot
SMSilvia Mazzaferro
Silvia Mazzaferro
JLJonathan Lavaud
Jonathan Lavaud
LVLaetitia Vanwonterghem
Laetitia Vanwonterghem
MHMaxime Henry
Maxime Henry
AHAmandine HURBIN
Amandine HURBIN

1 April 2018 in Cancer Letters
Verified
Journal Article
Closed access
MGMarie Guerard
Marie Guerard
TRThomas Robin
Thomas Robin
PPPascal Perron
Pascal Perron
AHAnne-Sophie Hatat
Anne-Sophie Hatat
LDLaurence David-Boudet
Laurence David-Boudet
SGSylvie Gazzeri
Sylvie Gazzeri

1 November 2016 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
VJVictor Jeannot
Victor Jeannot
BBBenoit Busser
Benoit Busser
LVLaetitia Vanwonterghem
Laetitia Vanwonterghem
SMSophie Michallet
Sophie Michallet
SFSana Ferroudj
Sana Ferroudj
AHAmandine HURBIN
Amandine HURBIN
Development of drug resistance limits the efficacy of targeted therapies. Alternative approaches using different combinations of therapeutic agents to inhibit several pathways could be a more effective strategy for treating cancer. The effects of the approved epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (gefitinib) or a multi-targeted kinase inhibitor (sorafenib) in combination with a histone deacetylase inhibitor (vorinostat) on cell proliferation, cell cycle distribution, apoptosis, and signaling pathway activation in human lung adenocarcinoma and hepatocarcinoma cells with wild-type EGFR and mutant KRAS were investigated. The effects of the synergistic drug combinations were also studied in human lung adenocarcinoma and hepatocarcinoma cells in vivo. The combination of gefitinib and vorinostat synergistically reduced cell growth and strongly induced apoptosis through inhibition of the insulin-like growth factor-1 receptor/protein kinase B (IGF-1R/AKT)-dependent signaling pathway. Moreover, the gefitinib and vorinostat combination strongly inhibited tumor growth in mice with lung adenocarcinoma or hepatocarcinoma tumor xenografts. In contrast, the combination of sorafenib and vorinostat did not inhibit cell proliferation compared to a single treatment and induced G2/M cell cycle arrest without apoptosis. The sorafenib and vorinostat combination sustained the IGF-1R-, AKT-, and mitogen-activated protein kinase-dependent signaling pathways. These results showed that there was synergistic cytotoxicity when vorinostat was combined with gefitinib for both lung adenocarcinoma and hepatocarcinoma with mutant KRAS in vitro and in vivo but that the combination of vorinostat with sorafenib did not show any benefit. These findings highlight the important role of the IGF-1R/AKT pathway in the resistance to targeted therapies and support the use of histone deacetylase inhibitors in combination with EGFR-tyrosine kinase inhibitors, especially for treating patients with mutant KRAS resistant to other treatments.

31 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PGPauline Gilson
Pauline Gilson
FPFernando Josa Prado
Fernando Josa Prado
BBeauvineau Claire
Beauvineau Claire
DNDelphine Naud-Martin
Delphine Naud-Martin
LVLaetitia Vanwonterghem
Laetitia Vanwonterghem
BBBenoit Busser
Benoit Busser
Despite the emergence of targeted therapies and immunotherapy, chemotherapy remains the gold-standard for the treatment of most patients with solid malignancies. Spindle poisons that interfere with microtubule dynamics are commonly used in chemotherapy drug combinations. However, their troublesome side effects and the emergence of chemoresistance highlight the need for identifying alternative agents. We performed a high throughput cell-based screening and selected a pyrrolopyrimidine molecule (named PP-13). In the present study, we evaluated its anticancer properties in vitro and in vivo. We showed that PP-13 exerted cytotoxic effects on various cancer cells, including those resistant to current targeted therapies and chemotherapies. PP-13 induced a transient mitotic blockade by interfering with both mitotic spindle organization and microtubule dynamics and finally led to mitotic slippage, aneuploidy and direct apoptotic death. PP-13 was identified as a microtubule-targeting agent that binds directly to the colchicine site in β-tubulin. Interestingly, PP-13 overcame the multidrug-resistant cancer cell phenotype and significantly reduced tumour growth and metastatic invasiveness without any noticeable toxicity for the chicken embryo in vivo. Overall, PP-13 appears to be a novel synthetic microtubule inhibitor with interesting anticancer properties and could be further investigated as a potent alternative for the management of malignancies including chemoresistant ones.